Automatic bone scan index for therapy response assessment of radium-223-dichloride (Ra-223) therapy in advanced prostate cancer

被引：0
|
作者：
Sakretz, M. [1 ]
Kurth, J. [1 ]
Schwarzenboeck, S. M. [1 ]
Krause, B. J. [1 ]
Heuschkel, M. [1 ]
机构：
[1] Univ Rostock, Dept Nucl Med, Med Ctr, D-18055 Rostock, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P748
引用
收藏
页码：S699 / S699
页数：1
相关论文
共 50 条
  • [41] Ra-223 alpha-Therapy in Patients with Bone Metastases from Castration-resistant Prostate Cancer
    Jessome, Rebecca
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2015, 46 (02) : 156 - 161
  • [42] The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer
    Wilson, James M.
    Parker, Christopher
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 911 - 918
  • [43] Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
    Kairemo, Kalevi
    Joensuu, Timo
    Rasulova, Nigora
    Kiljunen, Timo
    Kangasmaki, Aki
    DIAGNOSTICS, 2015, 5 (03): : 358 - 368
  • [44] Radiographic and laboratory assessment of bone metastases in castration-resistant prostate cancer patients undergoing Radium-223 dichloride therapy
    Takalkar, Amol
    Paryani, Bhavna
    Skweres, Justin
    Adams, Scott
    Devarakonda, Srinivas
    Dhawan, Manish
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [45] Investigation into the feasability of using EPDs to perform simple dosimetry modelling on Radium-223-dichloride therapy patients
    Shaylor, A. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S426 - S427
  • [46] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [47] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel (D) therapy in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S., I
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [48] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
    Finkelstein, Steven E.
    Michalski, Jeff M.
    O'Sullivan, Joe M.
    Parker, Chris
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345